



## Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and Consortium

August 8, 2016

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2016-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with the Milner Therapeutics Institute and Consortium.

The Milner Therapeutics Institute aims to accelerate academic research by forging collaborative interactions between scientists and the pharmaceutical industry to deliver better therapies for patients. The outreach arm of the Institute, the Milner Therapeutics Consortium, connects academic scientists and institutions in Cambridge, U.K., with the pharmaceutical industry to develop the therapeutic potential of their research. The Consortium consists of four major pharmaceutical companies, Astex, AstraZeneca, GlaxoSmithKline, and Shionogi, along with three academic centers, University of Cambridge, Babraham Institute, and Sanger Institute.

"Our partnership with the Milner Therapeutics Institute and Consortium further enables the collaboration between academics and pharmaceutical companies as they partner to investigate the therapeutic potential of their research," said Emily Hickey, DVM, Ph.D., Corporate Senior Vice President, Global Discovery Services at Charles River. "Charles River has had great success partnering with academic consortia in the United States, and we look forward to the same success in our first major research collaboration in the United Kingdom."

Through this partnership, the academic institutions in the Consortium will have access to Charles River's early discovery and drug development resources and services to accelerate their early-stage drug development processes. Charles River is the first full-service, early-stage contract research organization (CRO) to partner with the Milner Therapeutics Institute and Consortium.

"We are excited to welcome Charles River as the newest partner to the Milner Therapeutics Institute," said Tony Kouzarides, Founder and Director of the Milner Therapeutics Institute and Consortium. "Charles River is uniquely positioned to help guide novel therapies from early discovery through safety testing. Their scientific expertise and wealth of industry knowledge will provide significant collaborative opportunities for the scientists in our program."

The Milner Therapeutics Consortium was established in 2015 to act as a "match-making" service between pharmaceutical companies and researchers in Cambridge. The Consortium brings together the drug development capability of pharmaceutical companies with the discovery expertise of academic institutions in Cambridge and has been specifically modeled to facilitate the speedy exchange of resources and information between partners through a pre-signed agreement.

### About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit [www.criver.com](http://www.criver.com).

### About Milner Therapeutics Consortium

The Milner Therapeutics Consortium consists of four major pharmaceutical companies, (Astex, AstraZeneca, GlaxoSmithKline and Shionogi) and three academic centres (University of Cambridge, Babraham Institute and Sanger Institute). A Consortium agreement is in place to facilitate rapid exchange of reagents and information between partners in all therapeutic areas. Pharmaceutical partners set aside funds and use the Consortium agreement to collaborate with scientists in the academic centres. The Consortium is the outreach program of the Milner Therapeutics Institute which is under construction on the Cambridge Biomedical Campus and will open early in 2018.

The Milner also has an Affiliated partner scheme to enable members of the Consortium to engage and collaborate with technology or service providers. Charles River Laboratories will be a key partner in this endeavor.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160808006139/en/>

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

#### Investor Contact:

Susan E. Hardy, 781-222-6190

Corporate Vice President, Investor Relations

[susan\\_hardy@crl.com](mailto:susan_hardy@crl.com)

or

#### Media Contact:

Amy Cianciaruso, 781-222-6168

Corporate Vice President, Public Relations

[amy.cianciaruso@crl.com](mailto:amy.cianciaruso@crl.com)